Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

176results about How to "Improve drug delivery" patented technology

Pulsed cavitational ultrasound therapy

InactiveUS20070083120A1Enhance deliveryEnhance transportUltrasonic/sonic/infrasonic diagnosticsSurgeryBubble cloudMicrobubbles
Therapy methods using pulsed cavitational ultrasound therapy can include the subprocesses of initiation, maintenance, therapy, and feedback of the histotripsy process, which involves the creation and maintenance of ensembles of microbubbles and the use of feedback in order to optimize the process based on observed spatial-temporal bubble cloud dynamics. The methods provide for the subdivision or erosion of tissue, liquification of tissue, and the enhanced delivery of therapeutic agents. Various feedback mechanisms allow variation of ultrasound parameters and provide control over the pulsed cavitational process, permitting the process to be tuned for a number of applications. Such applications can include specific tissue erosion, bulk tissue homogenization, and delivery of therapeutic agents across barriers.
Owner:THE RGT OF THE UNIV OF MICHIGAN

Crosslinked hyaluronic acid compositions for tissue augmentation

A hyaluronic acid (HA) composition includes crosslinked, water-insoluble, hydrated HA gel particles. The HA includes crosslinks represented by the following structural formula: HA—U—R2—U—HA The variables are defined herein. A method of augmenting tissue in a subject includes inserting a needle into a subject at a location in the subject that is in need of tissue augmentation, wherein the needle is coupled to a syringe loaded with the HA composition, and applying force to the syringe, to deliver the HA composition into the subject. A method of preparing the HA composition, includes forming water-insoluble, dehydrated crosslinked HA particles, separating the water-insoluble, dehydrated particles by average diameter, selecting a subset of particles by average diameter, and hydrating the subset of dehydrated particles with a physiologically compatible aqueous solution. Another method of preparing the crosslinked HA composition includes crosslinking a precursor of the crosslinked HA with a biscarbodiimide in the presence of a pH buffer and dehydrating the crosslinked HA. Also included is a method of augmenting tissue in a subject that is in need of tissue augmentation. A method of stabilizing crosslinked HA includes hydrating water-insoluble, dehydrated crosslinked HA with a physiologically compatible aqueous solution that includes a local anesthetic, wherein the value of storage modulus G′ for the stabilized composition is at least about 110% of the value of G′ for a non-stabilized composition,. Also included is the stabilized HA composition.
Owner:ANIKA THERAPEUTICS INC

Glucosamine and glucosamine/Anti-inflammatory mutual prodrugs, compositions, and methods

Mutual prodrugs of glucosamine, and derivatives and analogs of glucosamine and an anti-inflammatory agent, compositions thereof, and methods for, e.g., treating disorders and conditions by administration of the compositions are provided. Topical compositions of glucosamine, and derivatives and analogs of glucosamine are also provided.
Owner:UNIV OF GEORGIA RES FOUND INC

Devices and Methods for Endovascular Therapies

InactiveUS20130023897A1Improve clinical outcomeFacilitate distribution , delivery , absorption and/or efficacySurgical instrument detailsEndovascular therapyPercent Diameter Stenosis
Medical devices to treat stenosis, inhibiting restenosis, plaque removal, crossing totally occluded arteries or veins, treatment of vulnerable plaque, as well as removal of blood clots from the patient body arc disclosed. Such devices maybe used alone or in combination with therapeutic drugs. In some embodiments, flow protection devices are used for homogeneous drug delivery and removal from the patient to minimize the systemic effect. In some other embodiments, ablated tissue or blood clots are removed from the body after the procedure.
Owner:CARDIOPROLIFIC INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products